INS and obesity disorder: A dual GLP-1/GDF15 agonist led to greater reductions in body weight, food intake, insulin, fasting glucose, and triglycerides compared to individual treatments (Zhang et al. 2023b), highlighting GDF15’s potential in obesity management.